Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.53 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.53 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.51 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | RORC | P51449 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL585357 | 1.00 | S1PR5 (0.53) | S1PR5S1PR1FUCA1USP30SIGMAR1 | |
| SCHEMBL6232433 | 1.00 | S1PR5 (0.53) | S1PR5S1PR1FUCA1USP30SIGMAR1 | |
| SCHEMBL6232439 | 1.00 | S1PR5 (0.53) | S1PR5S1PR1FUCA1USP30SIGMAR1 | |
| SCHEMBL9112639 | 0.95 | S1PR5 (0.52) | S1PR5S1PR1FUCA1USP30SIGMAR1 | |
| SCHEMBL585359 | 0.95 | S1PR5 (0.52) | S1PR5S1PR1FUCA1USP30SIGMAR1 | |
| SCHEMBL8229357 | 0.95 | S1PR5 (0.52) | S1PR5S1PR1FUCA1USP30SIGMAR1 | |
| SCHEMBL9112633 | 0.95 | S1PR5 (0.52) | S1PR5S1PR1FUCA1USP30SIGMAR1 | |
| SCHEMBL19064205 | 0.95 | S1PR5 (0.52) | S1PR5S1PR1FUCA1USP30SIGMAR1 | |
| SCHEMBL5119476 | 0.95 | S1PR5 (0.52) | S1PR5S1PR1FUCA1USP30SIGMAR1 | |
| SCHEMBL19121611 | 0.95 | S1PR5 (0.52) | S1PR5S1PR1FUCA1USP30SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025052278-A1 | PYRROLIDINE BASED CATIONIC LIPIDS FOR LIPID NANOPARTICLE DELIVERY OF THERAPEUTICS TO HEPATIC STELLATE CELLS | GENEVANT SCIENCES GMBH (CH) | 2025-03-13 | — | — | WO | disclosed |
| EP-4472963-A1 | DGK TARGETING COMPOUNDS AND USES THEREOF | Arvinas Operations, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| CN-118946556-A | DGK targeting compounds and uses thereof | 阿维纳斯运营公司 | 2024-11-12 | — | — | CN | disclosed |
| WO-2024109688-A1 | PYRROLE FUSED RING DERIVATIVE AND PHARMACEUTICAL USE THEREOF | 成都百裕制药股份有限公司 | 2024-05-30 | — | — | WO | disclosed |
| WO-2023150186-A1 | DGK TARGETING COMPOUNDS AND USES THEREOF | ARVINAS OPERATIONS, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023001069-A1 | MACROCYCLIC AMIDE COMPOUNDS AND APPLICATION THEREOF | 南京明德新药研发有限公司 | 2023-01-26 | — | — | WO | disclosed |
| EP-3334729-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND THEIR USE AS METAP2 INHIBITORS | Zafgen, Inc. (US) | 2018-06-20 | — | — | EP | disclosed |
| US-9580434-B2 | Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloalkanes | ATTENUA, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| WO-2017027687-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND THEIR USE AS METAP2 INHIBITORS | ZAFGEN, INC. (US) | 2017-02-16 | — | — | WO | disclosed |
| EP-2780342-B1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO LTD (CN) | 2016-06-01 | — | — | EP | disclosed |
| WO-2009111550-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOAL KANES | TARGACEPT, INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| EP-2094703-A1 | NICOTINIC ACETYLCHOLINE RECEPTORSUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES | Targacept, Inc. (US) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008057938-A1 | NICOTINIC ACETYLCHOLINE RECEPTORSUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES | TARGACEPT, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| EP-1259532-B1 | BILE ACIDS CONJUGATES WITH METAL ION CHELATES AND THE USE THEREOF | BRACCO IMAGING SPA (IT) | 2005-05-04 | — | — | EP | disclosed |
| US-6803030-B2 | CONTRAST AGENTS FOR MAGNETIC RESONANCE IMAGING | BRACCO IMAGING S.P.A. (IT) | 2004-10-12 | — | — | US | disclosed |
| US-6642255-B2 | Substituted carbocyclic or heterocyclic hydroxamic acid derivatives, e.g., (3R,4S)-N-hydroxy-1-methyl-3-(((4-((2-methyl-4 -quinolinyl)methoxylphenyl)sulfonyl)methyl)-4-piperidinecarboxamide | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-11-04 | — | — | US | disclosed |
| US-20030113265-A1 | Bile acids conjugates with metal ion chelates and the use thereof | BRACCO IMAGING S.P.A. (IT) | 2003-06-19 | — | — | US | disclosed |
| US-20030087890-A1 | 1,2,-Disubstituted cyclic inhibitors of matrix metalloproteases and TNF-alpha | BRISTOL-MYERS SQUIBB COMPANY, (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2003-05-08 | — | — | US | disclosed |
| EP-1259532-A1 | BILE ACIDS CONJUGATES WITH METAL ION CHELATES AND THE USE THEREOF | Bracco Imaging S.p.A. (IT) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001064708-A1 | BILE ACIDS CONJUGATES WITH METAL ION CHELATES AND THE USE THEREOF | BRACCO IMAGING S.P.A. (IT) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087890-A1 | 1,2,-Disubstituted cyclic inhibitors of matrix metalloproteases and TNF-alpha | MMP1, MMP8, MMP9 | S1PR5 2901/4885S1PR1 1667/4885FUCA1 658/4885 |
| US-20030113265-A1 | Bile acids conjugates with metal ion chelates and the use thereof | SLC10A2, SLC10A1, NR1H4 | S1PR5 2196/4885S1PR1 1690/4885FUCA1 2549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.